Clinical Trial Update: Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating oral tofacitinib in children aged 2 to 17 with moderate to severe ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Ulcerative Colitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING